These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 28229472)
1. Human capital gaps in vaccine development: an issue for global vaccine development and global health. Cawein A; Emini E; Watson M; Dailey J; Donnelly J; Tresnan D; Evans T; Plotkin S; Gruber W Ann N Y Acad Sci; 2017 May; 1395(1):3-11. PubMed ID: 28229472 [TBL] [Abstract][Full Text] [Related]
2. Collaborative funding for NCDs-a model of research funding. Davies J Lancet Diabetes Endocrinol; 2016 Sep; 4(9):725-727. PubMed ID: 27460309 [No Abstract] [Full Text] [Related]
3. Funding vaccines for emerging infectious diseases. Wong G; Qiu X Hum Vaccin Immunother; 2018 Jul; 14(7):1760-1762. PubMed ID: 29194012 [TBL] [Abstract][Full Text] [Related]
4. Infectious disease research investments: systematic analysis of immunology and vaccine research funding in the UK. Fitchett JR; Head MG; Atun R Vaccine; 2013 Dec; 31(50):5930-3. PubMed ID: 24176489 [TBL] [Abstract][Full Text] [Related]
5. Tracking global expenditures on surgery: gaps in knowledge hinder progress. Dieleman JL; Yamey G; Johnson EK; Graves CM; Haakenstad A; Meara JG Lancet Glob Health; 2015 Apr; 3 Suppl 2():S2-4. PubMed ID: 25926316 [No Abstract] [Full Text] [Related]
6. Creating a global observatory for health R&D. Terry RF; Salm JF; Nannei C; Dye C Science; 2014 Sep; 345(6202):1302-4. PubMed ID: 25214621 [TBL] [Abstract][Full Text] [Related]
7. A venture capital view of challenges, opportunities, and innovation in biomedical research. Ratcliffe LT Clin Pharmacol Ther; 2011 Feb; 89(2):174-6. PubMed ID: 21252935 [TBL] [Abstract][Full Text] [Related]
8. Economics and financing of vaccines for diarrheal diseases. Bartsch SM; Lee BY Hum Vaccin Immunother; 2014; 10(6):1568-81. PubMed ID: 24755623 [TBL] [Abstract][Full Text] [Related]
9. Financing children's vaccines. Nelson EA; Sack D; Wolfson L; Walker DG; Seng LF; Steele D Vaccine; 2009 Nov; 27 Suppl 5():F12-7. PubMed ID: 19931710 [TBL] [Abstract][Full Text] [Related]
11. Building the Human Vaccines Project: strategic management recommendations and summary report of the 15-16 July 2014 business workshop. Schenkelberg T; Kieny MP; Bianco AE; Koff WC Expert Rev Vaccines; 2015 May; 14(5):629-36. PubMed ID: 25673514 [TBL] [Abstract][Full Text] [Related]
12. The cancer megafund: determinants of success. Marko NF Nat Biotechnol; 2013 Jun; 31(6):492-4. PubMed ID: 23752428 [No Abstract] [Full Text] [Related]
13. Public sector seeks to bridge 'valley of death'. Moran N Nat Biotechnol; 2007 Mar; 25(3):266. PubMed ID: 17344867 [No Abstract] [Full Text] [Related]
14. Opportunities for vaccine research in Europe. Gancberg D; Hoeveler A; Martini A; Draghia-Akli R Hum Vaccin Immunother; 2015; 11(8):1917-20. PubMed ID: 26090718 [No Abstract] [Full Text] [Related]
16. Scientific challenges and opportunities in developing novel vaccines for the emerging and developing markets: New Technologies in Emerging Markets, October 16th-18th 2012, World Vaccine Congress, Lyon. Kochhar S Hum Vaccin Immunother; 2013 Apr; 9(4):928-31. PubMed ID: 23322007 [TBL] [Abstract][Full Text] [Related]
17. Roadmap for the establishment of a European vaccine R&D infrastructure. Leroy O; Geels M; Korejwo J; Dodet B; Imbault N; Jungbluth S Vaccine; 2014 Dec; 32(51):7021-7024. PubMed ID: 25148773 [TBL] [Abstract][Full Text] [Related]
18. Strengthening vaccination policies in Latin America: an evidence-based approach. Tapia-Conyer R; Betancourt-Cravioto M; Saucedo-Martínez R; Motta-Murguía L; Gallardo-Rincón H Vaccine; 2013 Aug; 31(37):3826-33. PubMed ID: 23357196 [TBL] [Abstract][Full Text] [Related]
19. A half-billion-dollar bid to head off emerging diseases. Cohen J Science; 2017 Jan; 355(6322):237. PubMed ID: 28104849 [No Abstract] [Full Text] [Related]
20. Letter from Bristol. Graham C; Rai D Natl Med J India; 2017; 30(6):356-357. PubMed ID: 30117454 [No Abstract] [Full Text] [Related] [Next] [New Search]